Clinical trials: malaria
Malaria
Optimal Chemopreventive Regimens to Prevent Malaria and Improve Birth Outcomes in Uganda
This trial tests the hypothesis that intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) + dihydroartemisin-piperaquine (DP) will significantly reduce the risk of adverse birth outcomes…
- Trial name
- NCT04336189
- Testing
- Sulfadoxine-pyrimethamine (SP), Dihydroartemisinin-piperaquine (DP)
- Where
- Uganda
- Volunteers
- 2,757 people, healthy volunteers welcome
- Sponsor
- Grant Dorsey, M.D, Ph.D.
Malaria, Malaria Infection
Malaria Vaccine for Children in Mali
This study will evaluate the safety and immune response of children to an experimental malaria vaccine called AMA1-C1/Alhydrogel® (Registered Trademark) + CPG 7909.
- Trial name
- NCT00740090
- Testing
- AMA1-C1/Alhydrogel plus CPG 7909
- Where
- Mali
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, With Matrix-M1 Adjuvant
This is a study in which healthy adult volunteers will be given either an experimental Malaria vaccine or a saline control vaccine. Each volunteer will receive three vaccinations in total.
- Trial name
- NCT02925403
- Testing
- R21/Matrix-M1, Saline
- Where
- Burkina Faso
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malnutrition, Malaria
Effectiveness of Nutritional Supplementation in Preventing Malnutrition in Children With Infection
The purpose of this study is to determine whether 14 days nutritional supplementation with Ready to use therapeutic Food (RUTF) or micronutrients alone to children having an infection will prevent malnutrition and reduce the…
- Conditions
- Malnutrition, Malaria, Lower Respiratory Tract Infection, Diarrhoea
- Trial name
- NCT01154803
- Testing
- Ready to Use Therapeutic Food (RUTF), Micronutrient Powder (MNP)
- Where
- Nigeria
- Volunteers
- 2,213 people
- Sponsor
- Medecins Sans Frontieres, Netherlands
Malaria
Molecular Basis of Erythrocyte Invasion by Plasmodium Vivax Into Duffy-Negative Erythrocytes in Mali
Background: Malaria is caused by parasites carried by some mosquitos. When the mosquitos bite people, the parasites can infect them. One of these parasites is Plasmodium vivax (P. vivax). Some children have P.
- Trial name
- NCT03304691
- Where
- 2 sites in Mali
- Volunteers
- 667 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Hati Salama (Secure Voucher)
The use of long-lasting insecticide treated nets (LLINs) is shown to reduce malaria prevalence. The Tanzania Net Voucher Scheme has been an active component of bed net distribution to pregnant women in Tanzania since 2004.
- Trial name
- NCT02561624
- Testing
- Behaviour change communication via text message
- Where
- Tanzania
- Volunteers
- 5,219 people, healthy volunteers welcome
- Sponsor
- Queen's University
Malaria
Safety and Efficacy Study of IV Artesunate to Treat Malaria
The purpose of this study is to determine how GMP IV Artesunate is metabolized and cleared by individuals with uncomplicated malaria infection and to determine how fast it eliminates malaria infection from the body.
- Trial name
- NCT00298610
- Testing
- Artesunate, Malarone
- Where
- Kenya
- Volunteers
- 30 people
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria, Dengue
Characterizing Humoral Immune Response to Mosquito Bites
The characteristics of the humoral response directed against mosquito saliva antigens are not known precisely. This is a major limitation for using immunological markers as an outcome in epidemiological trials and as an indicator…
- Trial name
- SG6 (NCT04478370)
- Testing
- Mosquito bites
- Where
- Thailand
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria,Falciparum
Safety and Immunogenicity of the Malaria Vaccine, R21/MatrixM, in Healthy Thai Adults
Malaria remains one of the leading causes of morbidity and mortality worldwide. Plasmodium falciparum is a complex pathogen with numerous immune evasion mechanisms which has added layers of complexity to the development of safe…
- Trial name
- R21/Matrix-M (NCT05252845)
- Testing
- R21/Matrix-M vaccination, DHA-PIP, PQ
- Where
- Thailand
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
Consistency of Immunogenicity and Non Inferiority of GSK Biologicals' Candidate Malaria Vaccine Lots in Children
The purpose of this study is to show the consistency of different lots of a candidate vaccine (257049) against malaria developed by GlaxoSmithKline (GSK) Biologicals.
- Trial name
- NCT01323972
- Testing
- GSK Biologicals' candidate Plasmodium falciparum malaria vaccine (257049)
- Where
- 2 sites in Nigeria
- Volunteers
- 327 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria
Artemisinin Resistance in Bangladesh
A randomized, controlled clinical trial conducted in Southeastern Bangladesh using artesunate monotherapy to determine the baseline sensitivity of P. falciparum to artemisinins.
- Trial name
- NCT00639873
- Testing
- Artesunate, quinine-doxycycline
- Where
- Bangladesh
- Volunteers
- 126 people
- Sponsor
- Medical University of Vienna
Malaria, Vivax
Radical CUREfor MAlaria Among Highly Mobile and Hard-to-reach Populations in the Guyanese Shield
The investigators are proposing a new malaria control strategy to reach the group of garimpeiros not reached by the usual actions of the health services.
- Trial name
- CUREMA (NCT05540470)
- Testing
- PART, Malakit, CROSS-SECTIONAL PRE- AND POST-INTERVENTION SURVEYS
- Where
- 2 sites in Brazil, Suriname
- Volunteers
- 1,991 people
- Sponsor
- Centre Hospitalier de Cayenne
Malaria
Safety and Efficacy Study of Artesunate and Mefloquin in Children With Uncomplicated Malaria
The present study aims to investigate and to assess possible neurological and neuropsychiatric events in young children in west Africa with uncomplicated P.
- Trial name
- NCT00978172
- Testing
- artesunate and mefloquine
- Where
- Cameroon
- Volunteers
- 220 people
- Sponsor
- Mepha Ltd.
Healthy Volunteers
Malaria: Relative Bioavailability and Food Effect of DSM265
Phase 1 study designed to evaluate the relative bioavailability of a single dose of a test formulation, DSM265-TPGS 34% SDD powder in comparison with a reference DSM265 25% SDD powder formulation used in early clinical trials.
- Trial name
- NCT03637517
- Testing
- DSM265-TPGS 34% SDD, 400 mg fasted, DSM265-TPGS 34% SDD, 400 mg fed, DSM265 25% SDD, 400 mg fasted
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria
Efficacy of Three ACTs for the Treatment of Falciparum Malaria in Maradi Niger
Study treatments: Artemether-lumefantrine Artesunate-amodiaquine Dihydroartemisinin-piperaquine Location: Maradi, Niger Principal Objective: To measure the clinical and parasitological efficacy of the three artemisinin…
- Trial name
- NCT01755559
- Testing
- Artesunate-amodiaquine, Dihydroartemisinin-piperaquine, Artemether-lumefantrine
- Where
- Niger
- Volunteers
- 663 people
- Sponsor
- Epicentre
Malaria, Antepartum
Safety and Immunogenicity of the Placental Malaria Vaccine Candidate PAMVAC Variously Adjuvanted
Despite having developed robust acquired immunity against complications of malaria, women can return to a susceptible state during their first pregnancies and contribute significantly to the burden of severe malaria in highly…
- Trial name
- PAMVAC (NCT02647489)
- Testing
- PAMVAC, Alhydrogel, GLA-SE
- Where
- Benin
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)
This was Cohort C2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.
- Trial name
- PLATINUM (NCT07811908)
- Testing
- KAE609, SoC (Coartem), KLU156
- Where
- 13 sites in Burkina Faso, Côte d’Ivoire and 5 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Malaria
Safety and Immunogenicity of New Malaria Vaccine Candidate ChAd63 CS Administered Alone and With MVA CS
This is an open label phase I study, to assess the safety of a novel malaria vaccine, AdCh63 CS, simian adenovirus encoding Plasmodium falciparum liver stage antigen, Circumsporozoite protein.
- Trial name
- NCT01450280
- Testing
- ChAd63 CS, ChAd63 CS, MVA CS, ChAd63, MVA CS
- Where
- Ireland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
Spatial Repellents for the Prevention of Malaria in Kenya
Spatial repellents are chemical-based devices that when placed in a room, make that room non-conducive for mosquitoes. These tools can be used to help in the fight against vector borne diseases such as malaria and dengue.
- Trial name
- AEGIS Kenya (NCT04766879)
- Testing
- Transfluthrin
- Where
- 2 sites in Kenya
- Volunteers
- 5,984 people, healthy volunteers welcome
- Sponsor
- University of Notre Dame
Malaria, Plasmodium Falciparum Malaria
CQSP in Malawi: Chloroquine and Sulfadoxine-pyrimethamine Efficacy for the Treatment of Malaria in Malawi
The purpose of this research study is to find out how well chloroquine works as a drug to treat malaria in children, compared to the standard malaria treatment in Malawi.
- Trial name
- NCT00125489
- Testing
- chloroquine sulfate, sulfadoxine/pyrimethamine
- Where
- Malawi
- Volunteers
- 210 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.